Zevra Therapeutics selects Orsini as specialty pharmacy partner for Olpruva

Zevra Therapeutics and Orsini Specialty Pharmacy announced that Orsini is now the pharmacy partner for Olpruva for oral suspension. Olpruva is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinic acid synthetase. UCDs are rare genetic disorders that impair the body’s ability to remove excess ammonia. People living with UCDs often suffer from ammonia buildup in the blood, potentially resulting in brain damage and neurocognitive impairments, coma and even death, if untreated. Olpruva is a nitrogen scavenger that removes excess ammonia.